Eli Lilly’s (NYSE:LLY | LLY Price Prediction) GLP-1 therapy Zepbound has become the biggest weight loss drug since its introduction, outpacing Novo Nordisk’s (NYSE:NVO) Wegovy in both sales momentum and patient preference.…
Rich Duprey Josh Brown, CEO of Ritholtz Wealth Management, made a pointed claim on CNBC’s Halftime Report this week about large-cap biotech: “These are growth stocks where you don’t have to worry about disruption.…
The market seems to be falling heavily out of love with the AI stocks, and for good reason: CapEx is rising at a staggering rate, especially among the Mag Seven AI darlings,…
Joey Frenette Eli Lilly (NYSE: LLY | LLY Price Prediction) stock has pulled back 2.9% year-to-date to around $1,044, and institutional investors have been accumulating shares during the pullback, according to recent filings. The…
Investors love dividend stocks because they provide dependable passive income streams and an excellent opportunity for solid total return. Total return includes interest, capital gains, dividends, and distributions realized over time. In…
Pre-Market Stock Futures: Futures are trading higher this morning, but what a difference a day makes after a “Meltdown Monday.” Stocks rallied on Tuesday, and all major indices closed higher. While not…
After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO | NVO Price Prediction) has dropped 22% in the past week and 56% over the past year, now sitting near its…
Editor’s note: A prior version of this article stated Eli Lilly and Nvidia had funded a supercomputer, when the commitment was for the co-innovation lab. This article has been updated to reflect…
AI-assisted drug discovery isn’t just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age. Undoubtedly, it’s no mystery as to why many wish to be underweight in the…
24/7 Wall St. provides estimates for future stock prices of Eli Lilly from 2026 to 2030 based on projected revenue and net income.
One of the biggest trends in the fight against obesity has been the explosion in popularity of GLP-1 medications. Created to treat diabetes, patients who were prescribed the popular GLP-1 drugs Ozempic,…
The rivalry in the GLP-1 market between pharmaceutical leaders Eli Lilly (NYSE:LLY | LLY Price Prediction) and Novo Nordisk (NYSE:NVO) has intensified following their latest fourth-quarter earnings reports. Novo Nordisk initially dominated…
Merck & Co. reports Q4 2025 earnings on Tuesday, Feb. 3, 2026, before market open. Wall Street expects earnings of $2.01 per share on revenue of $16.12 billion, representing 3.1% year-over-year growth.…
Shares of Altimmune (NASDAQ:ALT) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit. The clinical-stage biotech develops treatments for metabolic diseases and became one…
The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss drug revolution. The fund’s concentrated bet on GLP-1 manufacturers makes this a call option…
